We performed a comprehensive testing of a panel of BRCA1-mutant and comparable BRCA1-wild-type breast cancer cell lines for sensitivity to 198 approved and investigational drugs to identify common vulnerabilities. The gene discussed is BRCA1; the disease is breast cancer.